Latest market price
4.84
+0.12+2.43%
OverviewShort InterestFilings
SVRAQT39Savara Inc.·NASDAQ
4.84+2.43%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE+2.00%$23.43RARE+2.56%$16.72NUVB+2.29%$4.70TRAX+1.65%$45.80NTLA+4.63%$12.20ABSI+5.78%$10.25URGN-0.82%$34.08MAZE+2.22%$31.05
Snapshot
Index—P/E—EPS (ttm)-0.58Insider Own—Shs Outstand205.46MPerf Week4.65%
Market Cap971.83MForward P/E—EPS next Y-0.39Insider Trans-0.15%Shs Float102.98MPerf Month-1.66%
Enterprise Value828.83MPEG—EPS next Q-0.16Short Float27.91%Perf Quarter-12.57%
Income-139.00MP/S—EPS this Y—Short Ratio15.15Perf Half Y-10.75%
Sales0.00P/B6.75EPS next Y—ROA-72.50%Short Interest28.74MPerf YTD-21.56%
Book/sh0.70P/C5.62EPS next 5Y—ROE-90.28%52W High7.01 -30.88%Perf Year10.00%
Cash/sh0.84P/FCF—EPS past 3/5Y—ROIC-82.30%52W Low3.86 25.52%Perf 3Y34.76%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility5.95% 5.84%Perf 5Y294.17%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.28Perf 10Y—
Dividend Ex-Date—Quick Ratio10.13Sales Y/Y TTM—Profit Margin0.00%RSI (14)47.11Recom2.18
Dividend Gr. 3/5Y—Current Ratio10.13EPS Q/Q-14.29%SMA200.03%Beta0.30Target Price10.00
Payout0.00%Debt/Eq0.21Sales Q/Q—SMA50-6.48%Rel Volume0.89Prev Close4.73
Employees70LT Debt/Eq0.21EarningsNov 11SMA200-12.18%Avg Volume2.00MPrice4.84
IPO DateApr 28, 2017Option/ShortYes / YesEPS/Sales Surpr.-12.28% —Net Debt/EBITDA—Volume1,775,756Change2.43%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-07-26ReiteratedRBC Capital$10
Mar-16-26ReiteratedWilliam Blair$10
Dec-23-25ReiteratedUBS$10
Dec-23-25ReiteratedOppenheimerOutperform$11 → $10
Oct-23-25ReiteratedJMP SecuritiesMarket Outperform$9.00 → $11
Sep-09-25ReiteratedGuggenheimBuy$10 → $11
Aug-15-25UpgradeH.C. WainwrightNeutral → Buy$10 → $5.00
May-29-25DowngradeHC Wainwright & Co.Buy → Neutral
Nov-13-24DowngradeEvercore ISI GroupOutperform → In Line
Aug-13-24ReiteratedJMP SecuritiesMarket Outperform$10 → $9.00
Latest News· Times ET
Nov-02-26
Nov-02-2606:01AM
Savara Inc. (NASDAQ:SVRA) Sees Significant Drop in Short Interestdefenseworld.net
Oct-30-26
Oct-30-2607:15AM
Why Did Insmed Stock Jump?Yahoo
Oct-21-26
Oct-21-2601:10PM
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairmentbusinesswire.com
09:13AM
Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP PatientsBenzinga
Oct-13-26
Oct-13-2604:14AM
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?Yahoo
Oct-12-26
Oct-12-2604:05PM
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026businesswire.com
Oct-07-26
Oct-07-2606:08AM
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On WednesdayBenzinga
Aug-31-26
Aug-31-2604:21AM
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRAdefenseworld.net
Aug-27-26
Aug-27-2603:35AM
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRAdefenseworld.net
Aug-25-26
Aug-25-2604:19AM
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRAdefenseworld.net
Aug-24-26
Aug-24-2604:05PM
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026businesswire.com
12:08PM
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS CongressBenzinga
Aug-20-26
Aug-20-2604:05PM
Savara Announces New Employment Inducement Grantbusinesswire.com
Aug-18-26
Aug-18-2605:00PM
Top movers in Tuesday's after hours sessionChartMill
Aug-11-26
Aug-11-2604:05PM
Savara Reports Second Quarter 2026 Financial Results and Provides Business Updatebusinesswire.com
Company

Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A2107844—————
Gross Profit-210-78-44—————
Selling, General and Administrative Excl. Other58422516—————
Research and Development87817844—————
Other Operating Expense-220-78-44—————
Operating Income-143-124-103-60—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)5575—————
Net Income Before Taxes-139-119-96-55—————
Income Taxes
0000—————
Consolidated Net Income-139-119-96-55—————
Net Income From Continuing Operations-139-119-96-55—————
Net Income-139-119-96-55—————
EPS (Recurring)-0.58-0.53-0.48-0.33—————
EPS (Basic, Before Extraordinaries)-0.58-0.53-0.48-0.33—————
EPS (Diluted)-0.58-0.53-0.48-0.33—————
EBITDA-138-119-102-59—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding254222198165—————
Market Capitalization1,2311,339608776—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$7.51$6.28$5.04$3.81$2.57● Close Price0.00M0.56M1.12M1.68M2.24MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Lowrance David LChief Financial OfficerJun 22 '26Option Exercise1.76580,1871,021,117983,947Jun 22
Lowrance David LChief Financial OfficerJun 22 '26Sale5.68394,5282,241,432536,032Jun 22
Lowrance David LChief Financial OfficerMar 18 '26Option Exercise1.60366,747588,456552,550Mar 20
McCracken Joseph SDirectorFeb 16 '26Option Exercise1.761,8073,180302,644Feb 17
RAMSAY DAVID ADirectorDec 19 '25Sale6.0620,000121,2202,533,642Dec 19
Elam Nevan CDirectorDec 02 '25Option Exercise1.465,8608,55668,360Dec 04
Hawkins Richard JDirectorNov 14 '25Option Exercise1.465,8608,556121,326Nov 17
Hawkins Richard JDirectorJun 20 '25Buy2.0448,22598,572115,466Jun 23
McCracken Joseph SDirectorMay 29 '25Buy2.0810,00020,825260,837Jun 02
RAMSAY DAVID ADirectorMar 31 '25Buy2.77150,000416,2502,513,642Apr 01
Hawkins Richard JDirectorDec 16 '24Sale3.328,00026,56967,241Dec 16
Pauls MatthewCHIEF EXECUTIVE OFFICERDec 16 '24Sale3.3154,702180,8281,536,379Dec 16
Lowrance David LChief Financial OfficerDec 16 '24Sale3.3325,00083,278381,005Dec 16
McCracken Joseph SDirectorNov 19 '24Buy2.9520,00059,072210,837Nov 20
RAMSAY DAVID ADirectorNov 18 '24Buy2.88100,000287,6002,323,642Nov 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.